

Online Supplement

Health Care Professionals' Herpes Zoster Awareness and Vaccine Recommendations for Patients with COPD

Barbara P. Yawn, MD, MSc, MSPH^{1,2*} Natalia Y. Loskutova, MD, PhD^{3*} Debora D. Merrill, MBA² Sergio Martinez² Elisabeth Callen, PhD,³ Janice Cotton, MA² Jennifer K. Carroll, MD, MPH^{3,4} Dennis Williams, PharmD⁵

¹ Department of Family and Community Health, University of Minnesota, Minneapolis, Minnesota, United States

²COPD Foundation, Miami, Florida, United States

³ American Academy of Family Physicians National Research Network, Leawood, Kansas, United States

⁴ Department of Family Medicine, University of Colorado, Aurora, Colorado, United States

⁵ Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina, United States

Table of Contents for Supplemental Materials:

Supplemental Table 1. Burden of HZ by patient age group.

Supplemental Table 2. Vignette response. Full Responses to cases—all options included.
“Would you recommend vaccines to these patients?”

Supplementary Table 3. HZ vaccines recommended by HCP group.

Supplementary Table 4. Vaccine administration and referrals by HCP group. (Could provide multiple responses)

Supplementary Table 5. Barriers to HZ vaccinations by HCP type.

Supplementary Table 6: Did the video provide you with any new information on HZ (shingles)?

Supplementary Table 7: How helpful was the information in the video regarding increased risk of HZ (shingles) in patients with COPD for the following situations?

Supplementary Table 8. After watching the video, will you make any changes to recommending vaccines to your patients with COPD?

HCP Survey

Supplementary Table 1. Burden of HZ sufficient to warrant vaccine recommendation by patient age group.

	N	Strongly agree n, %	Somewhat agree n, %	Not sure n, %	Somewhat disagree n, %	Strongly disagree n, %
Among patients with COPD ages 50-59 years						
FPs	229	145, 63.3	55, 24.0	18, 7.9	7, 3.1	4, 1.7
Pulmonologists	258	106, 41.1*	72, 27.9	52, 20.2	14, 5.4	14, 5.4
NPs	250	148, 59.2	59, 23.6	27, 10.8	9, 3.6	7, 2.8
PAs	283	156, 55.1	76, 26.9	31, 11.0	13, 4.6	7, 2.5
Among patients with COPD ages 60-69 years						
	229	190, 83.0	29, 12.7	6, 2.6	3, 1.3	1, 0.4
Pulmonologists	258	172, 66.7*	36, 14.0	26, 10.1	11, 4.3	13, 5.0
NPs	250	189, 75.6	35, 14.0	13, 5.2	6, 2.4	7, 2.8
PAs	283	220, 77.7	37, 13.1	17, 6.0	2, 0.7	7, 2.5
Among patients with COPD ages 70-79 years						
FPs	229	192, 83.8	28, 12.2	5, 2.2	3, 1.3	1, 0.4
Pulmonologists	258	180, 69.8*	30, 11.6	26, 10.1	11, 4.3	11, 4.3
NPs	250	190, 76.0	30, 12.0	17, 6.8	9, 3.6	4, 1.6
PAs	283	225, 79.5	31, 11.0	18, 6.4	2, 0.7	7, 2.5
Among patients with COPD ages 80+						
FPs	229	176, 76.9**	38, 16.6	11, 4.8	3, 1.3	1, 0.4
Pulmonologists	258	164, 63.6	41, 15.9	30, 11.6	12, 4.7	11, 4.3
NPs	250	159, 63.6	50, 20.0	25, 10.0	12, 4.8	4, 1.6
PAs	283	196, 69.3	39, 13.8	38, 13.4	4, 1.4	6, 2.1

*Pulmonologists lower rates of strongly agree than all others, $P < .001$

**FPs higher rates than all others, $P < .01$

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

Supplementary Table 2. Full Responses to cases—all options included. “Would you recommend vaccines to these patients?”

	N	HZ (Shingles) vaccine(s)			Any Pneumococcal/ Pneumonia vaccine(s)			Influenza vaccine		
		Yes n, %	No n, %	Unsure n, %	Yes n, %	No n, %	Unsure n, %	Yes n, %	No n, %	Unsure n, %
52-year-old man with Chronic Bronchitis										
FPs	229	183, 79.9	27, 11.8	19, 8.3	212, 92.6	7, 3.1	10, 4.4	228, 99.6	1, 0.4	0, 0.0
Pulmonologists	256	151, 59.0	63, 24.6	42, 16.4	214, 83.6	35, 13.7	7, 2.7	256, 100.0	0, 0.0	0, 0.0
NPs	250	186, 74.4	37, 14.8	27, 10.8	229, 91.6	17, 6.8	4, 1.6	240, 96.0	10, 4.0	0, 0.0
PAs	283	211, 74.6	42, 14.8	30, 10.6	256, 90.5	17, 6.0	10, 3.5	281, 99.3	0, 0.0	2, 0.7
65-year-old woman with COPD on triple therapy (ICS, LABA, LAMA)										
FPs	229	225, 98.3	1, 0.4	3, 1.3	227, 99.1	2, 0.9	0, 0.0	228, 99.6	1, 0.4	0, 0.0
Pulmonologists	256	233, 91.0	4, 1.6	19, 7.4	253, 98.8	2, 0.8	1, 0.4	256, 100.0	0, 0.0	0, 0.0
NPs	250	232, 92.8	6, 2.4	12, 4.82	242, 96.8	4, 1.6	4, 1.6	248, 99.2	2, 0.8	0, 0.0
PAs	283	267, 94.3	2, 0.7	14, 4.9	279, 98.6	0, 0.0	4, 1.4	280, 98.9	1, 0.4	2, 0.7
55-year-old man with COPD on only as needed SABA										
FPs	229	191, 83.4	20, 8.7	18, 7.9	216, 94.3	7, 3.1	6, 2.6	228, 99.6	1, 0.4	0, 0.0
Pulmonologists	256	154, 60.2	63, 24.6	39, 15.2	216, 84.4	31, 12.1	9, 3.5	255, 99.6	1, 0.4	0, 0.0
NPs	250	195, 78.0	30, 12.0	25, 10.0	230, 92.0	18, 7.2	2, 0.8	243, 97.2	5, 2.0	2, 0.8
PAs	283	219, 77.4	40, 14.1	24, 8.5	249, 88.0	21, 7.4	13, 4.6	280, 98.9	1, 0.4	2, 0.7
75-year-old man with COPD and a history of chemotherapy and radiation RX but now in remission from lung cancer										
FPs	229	218, 95.2	4, 1.7	7, 3.1	223, 97.4	3, 1.3	3, 1.3	228, 99.6	1, 0.4	0, 0.0
Pulmonologists	256	234, 91.4	5, 2.0	17, 6.6	253, 98.8	2, 0.8	1, 0.4	255, 99.6	1, 0.4	0, 0.0
NPs	250	210, 84.0	16, 6.4	24, 9.6	240, 96.0	6, 2.4	4, 1.6	239, 95.6	6, 2.4	5, 2.0
PAs	283	246, 86.9	8, 2.8	29, 10.2	274, 96.8	2, 0.7	7, 2.5	280, 98.9	0, 0.0	3, 1.1
68-year-old woman with COPD and history of shingles in 2005										
FPs	229	218, 95.2	2, 0.9	9, 3.9	223, 97.4	4, 1.7	2, 0.9	228, 99.6	1, 0.4	0, 0.0
Pulmonologists	256	215, 84.0	13, 5.1	28, 10.9	254, 99.2	2, 0.8	0, 0.0	255, 99.6	1, 0.4	0, 0.0
NPs	250	221, 88.4	14, 5.6	15, 6.0	241, 96.4	8, 3.2	1, 0.4	239, 95.6	10, 4.0	1, 0.4
PAs	283	251, 88.7	10, 3.5	22, 7.8	280, 98.9	1, 0.4	2, 0.7	281, 99.3	0, 0.0	2, 0.7
80-year-old man with Emphysema										
FPs	229	214, 93.4	5, 2.2	10, 4.4	219, 95.6	5, 2.2	5, 2.2	228, 99.6	1, 0.4	0, 0.0
Pulmonologists	256	223, 87.1	8, 3.1	25, 9.8	250, 97.7	5, 2.0	1, 0.4	254, 99.2	1, 0.4	1, 0.4
NPs	250	222, 88.8	17, 6.8	11, 4.4	243, 97.2	5, 2.0	2, 0.8	239, 95.6	9, 3.6	2, 0.8
PAs	283	253, 89.4	5, 1.8	25, 8.8	274, 96.8	4, 1.4	5, 1.8	280, 98.9	1, 0.4	2, 0.7

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

Supplementary Table 3. HZ vaccines recommended by HCP group.

	FPs (N=229) n, %	Pulmonologists (N=258) n,%	NPs (N=250) n,%	PAs (N=283) n,%
What is the minimum age for general ACIP HZ vaccine recommendation?				
40 years	4, 1.7	12, 4.7	7, 2.8	10, 3.5
50 years	192, 83.8*	155, 60.1***	189, 75.6	200, 70.7
60 years	19, 8.3	43, 16.7	35, 14.0	34, 12.0
65 years	7, 2.6	18, 7.0	8, 3.2	15, 5.3
70 years	1, 0.4	1, 0.4	1, 0.4	1, 0.4
Never	1, 0.4	1, 0.4	0, 0.0	0, 0.0
Do not know	6, 2.6	28, 10.9+	10, 4.0	23, 8.1
Which types of HZ vaccines do you recommend?				
None	6, 2.6	54, 20.9	13, 5.2	34, 12.0
Either Zostavax (1-dose) or Shingrix (2-dose)	22, 9.6**	64, 24.8	61, 24.4	67, 23.7
Zostavax (1-dose) only	6, 2.6	18, 7.0	30, 12.0	16, 5.7
Shingrix (2-dose) only	200, 87.3*	124, 48.1***	156, 62.4	169, 59.7
Shingrix for those who previously had Zostavax	125, 54.6*	36, 14.0++	85, 34.0	102, 36.0

*FPs significantly more likely to recommend than all others $P<.001$

**FPs significantly less likely to recommend than all others $P<.001$

***Pulmonologists least likely to recommend compared to all others $P<.01$

+Pulmonologists more likely to no know than FPs $P<.01$

++Pulmonologists less like to recommend than all others $P<.01$

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

Supplementary Table 4. Vaccine administration and referrals by HCP group. (Could provide multiple responses)

	FPs (N=229) n,%	Pulmonologists (N=258) n,%	NPs (N=250) n,%	PAs (N=283) n,%
Annual Influenza				
I stock and administer in my office	208, 90.8*	198, 76.7	190, 76.0	216, 76.3
I refer to other offices like primary care	10, 4.4	59, 23.0	29, 11.6	49, 17.3
I refer to pharmacies	64, 27.9	88, 34.4	86, 34.4	70, 24.7
I refer to public health sites	23, 10.0	24, 9.4	34, 13.6	36, 12.7
Any pneumococcal/pneumonia				
I stock and administer in my office	193, 84.3*	179, 69.6	151, 60.4	168, 59.4
I refer to other offices like primary care	15, 6.6	69, 27.0	37, 14.8	79, 24.7
I refer to pharmacies	64, 27.9	86, 33.6	106, 42.4	84, 29.7
I refer to public health sites	20, 8.7	20, 7.8	43, 17.2	35, 12.4
HZ (shingles)				
I stock and administer in my office	106, 46.3	23, 9.0**	64, 25.6	104, 36.7
I refer to other offices like primary care	13, 5.7	136, 53.1	40, 16.0	80, 28.3
I refer to pharmacies	155, 67.7	140, 54.7	173, 69.2	150, 53.0
I refer to public health sites	24, 10.5	21, 8.2	42, 16.8	33, 11.7

*FPs more likely to stock and administer compared to all other HCP $P < .001$

**Pulmonologists less likely to stock and administer compared to all other HCP $P < .001$

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

Supplementary Table 5. Barriers to HZ vaccinations by HCP type.

	N	Not a barrier n, %	Minor barrier n, %	Major barrier n, %	Not applicable to my scope of practice n, %	Unsure n, %
Cost of vaccine						
FPs	229	30, 13.1	57, 24.9	133, 58.1	5, 2.2	4, 1.7
Pulmonologists	258	80, 31.0*	95, 36.8	39, 15.1+	20, 7.8	24, 9.3
NPs	250	55, 22.0	77, 30.8	101, 40.4	4, 1.6	13, 5.2
PAs	283	65, 23.0	77, 27.2	85, 30.0	28, 9.9	28, 9.9
Not covered by patient's insurance						
FPs	229	27, 11.8	47, 20.5	149, 65.1	4, 1.7	2, 0.9
Pulmonologists	258	60, 23.3*	76, 29.5	74, 28.7+	20, 7.8	28, 10.9
NPs	250	34, 13.6	57, 22.8	141, 56.4	4, 1.6	14, 5.6
PAs	283	36, 12.7	65, 23.0	123, 43.5	30, 10.6	29, 10.2
Coverage is by Medicare Part D (not B)						
FPs	229	33, 14.4	61, 26.6	113, 49.3	4, 1.7	18, 7.9
Pulmonologists	258	69, 26.7*	77, 29.8	26, 10.1+	19, 7.4	67, 26.0
NPs	250	51, 20.4	84, 33.6	68, 27.2	7, 2.8	40, 16.0
PAs	283	48, 17.0	67, 23.7	67, 23.7	33, 11.7	68, 24.0
My concerns about vaccine safety						
FPs	229	190, 83.0	27, 11.8	8, 3.5	3, 1.3	1, 0.4
Pulmonologists	258	191, 74.0**	39, 15.1	5, 1.9	12, 4.7	11, 4.3
NPs	250	200, 80.0	38, 15.2	9, 3.6	1, 0.4	2, 0.8
PAs	283	224, 79.2	38, 13.4	0, 0.0	14, 4.9	7, 2.5
My concerns about vaccine effectiveness						
FPs	229	193, 84.3	26, 11.4	4, 1.7	4, 1.7	2, 0.9
Pulmonologists	258	199, 77.1**	31, 12.0	5, 1.9	10, 3.9	13, 5.0
NPs	250	207, 82.8	29, 11.6	10, 4.0	2, 0.8	2, 0.8
PAs	283	224, 79.2	41, 14.5	1, 0.4	13, 4.6	4, 1.4
More pressing medical issues take precedence						
FPs	229	77, 33.6	103, 45.0	44, 19.2	3, 1.3	2, 0.9
Pulmonologists	258	103, 39.9	88, 34.1	51, 19.8	10, 3.9	6, 2.3
NPs	250	100, 40.0	103, 41.2	43, 17.2	2, 0.8	2, 0.8
PAs	283	86, 30.4	131, 46.3	45, 15.9	17, 6.0	4, 1.4
Trouble getting vaccine due to supply issues						
FPs	229	78, 34.1	78, 34.1	60, 26.2	10, 4.4	3, 1.3
Pulmonologists	258	93, 36.0	83, 32.2	37, 14.3++	26, 10.1	19, 7.4
NPs	250	91, 36.4	78, 31.2	60, 24.0	10, 4.0	11, 4.4
PAs	283	88, 31.1	99, 35.0	51, 18.0	23, 8.1	22, 7.8

*Pulmonologists more likely to say “not a barrier” compared to all other HCP, $P < .01$

**Pulmonologists less likely to say “not a barrier” compared to all other HCPs, $P < .03$

+Pulmonologists less likely to report “major barrier” compared to all others, $P < .001$

++Pulmonologists less likely to report “major barrier” compared to FPs and NPs, $P < .01$

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

Supplementary Table 6: Did the video provide you with any new information on HZ (shingles)?

	FPs (N=100) n,%	Pulmonologists (N=211) n,%	NPs (N=168) n,%	PAs (N=129) n,%
General information on risk and burden of HZ (shingles)				
All new	5, 5.0	55, 26.1*	31, 18.5	10, 7.8
Somewhat new	52, 52.0	134, 63.5	96, 57.1	86, 66.7
No new information	43, 43.0**	22, 10.4	41, 24.4	33, 25.6
Increased risk of HZ (shingles) in patients with COPD				
All new	46, 46.0	96, 45.5	86, 51.2	61, 47.3
Somewhat new	40, 40.0	78. 37.0	63. 37.5	54, 41.9
No new information	14. 14.0	37. 17.5	19, 11.3	14. 10.9
Complications of HZ (shingles)				
All new	2, 2.2	22,10.4	15. 8.9	8, 6.2
Somewhat new	20, 20.0	65, 30.8	47. 28.0	34, 26.4
No new information	78. 78.0	124. 58.8	106. 63.1	87. 67.4
Information on the two types of HZ (shingles) vaccines				
All new	5, 5.0	58, 27.5*	28, 16.7	17, 13.2
Somewhat new	22, 22.0	109, 51.7	80, 47.6	67. 51.9
No new information	73, 73.0	44, 20.9	60, 35.7	45, 34.9
Information on the current recommendations for giving HZ (shingles) vaccines				
All new	7, 7.0	59, 28.0*	36, 21.4	20, 15.5
Somewhat new	39, 39.0	123, 58.3	94, 56.0	81, 62.8
No new information	54, 54.0***	29. 13.7	38. 22.6	28, 21.7

*Pulmonologists more likely to report all new information compared to all other HCP, $P < .03$

**FP more likely to report no new information compared to all other HCP, $P < .01$

*** FP more likely to report no new information compared to all other HCP, $P < .001$

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

Supplementary Table 7: How helpful was the information in the video regarding increased risk of HZ (shingles) in patients with COPD for the following situations?

	FPs (N=100) n,%	Pulmonologists (N=211) n,%	NPs (N=168) n,%	PAs (N=129) n,%
Talking with patients about or recommending HZ (shingles) vaccines				
Very helpful	35, 35.0*	137, 64.9	117, 69.6	68, 52.7
Somewhat helpful	41, 41.0	67, 31.8	47, 28.0	54, 41.9
Not sure	11, 11.0	4, 1.9	1, 0.6	1, 0.8
Not very helpful	4, 4.0+	1, 0.5	3, 1.8	5, 3.9
Not at all helpful	9, 9.0+	2, 0.9	0, 0.0	1, 0.8
Consideration of adding HZ (shingles) to vaccines given in your office				
Very helpful	23, 23.0*	104, 49.3	91, 54.2	48, 37.2
Somewhat helpful	33, 33.0	56, 26.5	47, 28.0	45, 34.9
Not sure	14, 14.0	30, 14.2	17, 10.1	20, 15.5
Not very helpful	9, 9.0++	7, 3.3	11, 6.5	8, 6.2
Not at all helpful	21, 21.0++	14, 6.6	2, 1.2	8, 6.2

*FPs less likely to report very helpful compared to all other HCPs, $P < .001$

+FPs more likely to report not very or not at all helpful compared to all other HCPs, $P < .01$

++FPs more likely to report not very or not at all helpful compared to all other HCPs, $P < .001$

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

Supplementary Table 8. After watching the video, will you make any changes to recommending vaccines to your patients with COPD?

	FPs (N=57) n, %	Pulmonologists (N=183) n, %	NPs (N=128) n, %	PAs (N=92) n, %
More likely to recommend shingles vaccines to patients with COPD	52, 91.2	177, 96.7	124, 96.9	91, 98.9
Less likely to recommend shingles vaccines to patients with COPD	2, 3.5	3, 1.6	2, 1.6	1, 1.1
I am unlikely to add recommendations for shingles vaccines to care of patients with COPD – no change	3, 5.3	3, 1.6	2, 1.6	0, 0.0

Abbreviations: FPs=family physicians, NPs=nurse practitioners, PAs=physician assistants

HealthCare Professional Survey

INTRODUCTION: This study is being done by the COPD Foundation in collaboration with several professional societies. The purpose is to better understand knowledge, attitudes, and beliefs as well as current adult vaccine recommendations given by clinicians caring for adults with COPD.

Upon completion of the survey you will have chance to register in a drawing for a chance to win [PAs= one of ten \$25 -OR- Pulmonologists= one of five \$50] gift cards.

For questions, concerns or complaints about the research study, please call the COPD Foundation at 866-731-2673. All data will be kept confidential and will be anonymized (cannot be linked to your name or email address, or other personally identifiable information).

Participation is voluntary and a decision not to participate or to discontinue your participation will not result in any penalty or loss of benefits to which you are otherwise entitled. Your alternative is not to participate. Participation involves the completion of a survey for Physicians and Physician Assistants. You will not receive any direct benefit by participating, but we hope that the data collected will benefit the COPD community with improved information regarding vaccines.

Screening question: Is your primary practice located in the U.S.?

Yes [[proceed](#)]

No [[Exit to End Page Content #1](#)]

1. What is your age in years?

- a. 25-34
- b. 35-44
- c. 45-54
- d. 55-64
- e. 65-74
- f. >74

2. What is your gender?

Male Female Prefer not to answer Other: [Text box _____]

3. What is your current position?

- a. MD/DO—family physician
- b. MD/DO—pulmonologist
- c. NP working in primary care
- d. NP working in pulmonology
- e. PA working in primary care
- f. PA working in pulmonology
- g. Other: [Text box]_____

4. How many years have you worked in that specialty?

8. What is the minimum age your patients with COPD should receive a HZ (shingles) vaccine?

- a. 40 years
- b. 50 years
- c. 60 years
- d. 65 years
- e. 70 years
- f. Never
- g. Do not know

9. For each age group below, please indicate to what extent you agree or disagree with the following statement: HZ (shingles), post herpetic neuralgia and HZ eye complications cause sufficient burden to recommend HZ (shingles) vaccine in my patients with COPD: **(Please choose an answer in each line)**

	Strongly agree	Somewhat agree	Not sure	Somewhat disagree	Strongly disagree
Ages 50-59					
Ages 60-69					
Ages 70-79					
Age 80+					

10. How strongly do you recommend the following vaccines for your patients with COPD? **(Please choose an answer in each line)**

	Strongly recommended	Recommend but not strongly	No recommendation either for or against	Recommend against	Strongly Recommend Against
Annual influenza in ages 50-64					
Annual influenza in ages 65+					
Pneumococcal/Pneumonia vaccines in ages 50-64					
Pneumococcal/Pneumonia vaccines in ages 65+					
HZ (shingles) vaccine(s) in ages 50-64					
HZ (shingles) vaccine(s) in ages 65+					

11. For each statement below, please select how much of a barrier it is for recommending the HZ (shingles) vaccine in your patients with COPD? (**Please choose an answer in each line**)

	Not a barrier	Minor barrier	Major barrier	Not applicable to my scope of practice	Unsure
Cost of vaccine					
Not covered by patient's insurance					
Coverage is by Medicare Part D (not B)					
My concerns about vaccine safety					
My concerns about vaccine effectiveness					
More pressing medical issues take precedence					
Trouble getting vaccine due to supply issues					

12. What options are available for your patients with COPD to receive the vaccines listed below? (**Check all that apply in each line**)

	I stock and administer in my office	I refer to other offices like primary care	I refer to pharmacy	I refer to public health sites	I do not know
Annual Influenza					
Any pneumococcal/pneumonia					
HZ (shingles)					

13. Which of the HZ (shingles) vaccines do you most frequently recommend for people with COPD beginning at age 50 (**Choose all that apply**)?

- a. None
- b. Either Zostavax (1-dose) or Shingrix (2-dose)
- c. Zostavax (1-dose) only
- d. Shingrix (2-dose) only
- e. Shingrix for those who previously had Zostavax

14. Please select the option that best describes how the SARS-CoV2 (COVID) pandemic has changed your approach to recommending adult vaccines
- a. No change – still recommend
 - b. No change – never recommended
 - c. Delaying all vaccines
 - d. Unsure of what to do about recommending
 - e. Other – (please explain)

Next Steps

Respondent automatically moved forward to video and post-video questions if any of the following:

(Question – response)

Q6 – b, c, or d

Q7 – any “No” or “Unsure”, only on the HZ (Shingles) vaccine column

Q8 – a, c, d, e, f, or g

Q9 – “Not sure”, “somewhat disagree” or “strongly disagree” on any row

Q10 – “No recommendation”, “Recommend against” or “Strongly recommend against” on the HZ vaccine ages 50-64 and HZ vaccine ages 65+ rows

Q12 – “I don’t know” on HZ (shingles) row

Q13 – a or c

Otherwise, respondent sent to survey end and exit script [Exit to End Page Content #2]

Please watch the following 5-minute video on COPD and herpes zoster and answer the questions after completing the video.

Embedded video

After video questions:

15. Did the video provide you with any new information on HZ (shingles)?
- a. General information on risk and burden of HZ (shingles)
___ Yes, all new ___ Yes, somewhat new ___ No new information
 - b. Increased risk of HZ (shingles) in people with COPD
___ Yes, all new ___ Yes, somewhat new ___ No new information
 - c. Complications of HZ (shingles)
___ Yes, all new ___ Yes, somewhat new ___ No new information
 - d. Information on the two types of HZ (shingles) vaccines
___ Yes, all new ___ Yes, somewhat new ___ No new information

e. Information on the current recommendations for giving HZ (shingles) ____ Yes, all new ____ Yes, somewhat new ____ No new information

16. How helpful was the information in the video regarding increased risk of HZ (shingles) in people with COPD for the following situations: **(Please choose an answer in each line)**

	Very helpful	Somewhat helpful	Not sure	Not very helpful	Not helpful at all
Talking with patients about or recommending HZ (shingles) vaccines					
Consideration of adding HZ (shingles) to vaccines given in your office					

17. After watching the video, will you make any changes to recommending vaccines to your patients with COPD **(Please choose the best single answer for you)?**

____ More likely to recommend shingles vaccines to people with COPD

____ Less likely to recommend shingles vaccines to people with COPD

____ I already routinely recommend shingles vaccines to people with COPD—no change

____ I am unlikely to add recommendations for shingles vaccines to care of people with COPD—no change

18. For your patients with COPD, how strongly will you recommend HZ (shingles) vaccine in the future?

	Strongly recommended	Recommended	Won't recommend for or against	Recommended against	Strongly recommend against
Shingles (2-dose) Shingrix vaccine					
Shingles (1-dose) Zostavax vaccine					

Thank you. [\[Exit to End Page Content #2\]](#)